Method and composition for an improved bioavailability delivery system
AssigneeAmericana Pharma LLC
InventorAman Beri
Life of this patent
Estimating the term…
Abstract
A polarity-specific, multi-route delivery system for dietary supplement bioactives with each active pre-mapped to an optimized carrier tailored for oral, transdermal, or topical delivery. A unified formulation stability framework incorporates antioxidants, photoprotectants, oxygen scavengers, and nitrogen-flushed packaging, ensuring integrity under ICH Q1A(R2) conditions. The system supports modular formulations combining esterified DHEA analogs with adaptogens, minerals, amino acids, polyphenols, fatty acids, and vitamins, including coordinated oral-dermal or oral-transdermal regimens. Embodiments demonstrate enhanced nutrient bioavailability, reduced dosing frequency, and multi-phasic nutritional support for anabolic, metabolic, cognitive, cardiovascular, and healthy aging outcomes.
Claims20
A method of forming a targeted release dietary supplement delivery system comprising the steps of:
- micronizing a quantity of a DHEA derivative comprising 4-androstene-3bol-one propionate until the compound is in a dry, free-flowing powder form of less than ten microns and performing a quality control of the micronized DHEA derivative and determining that no chemical degradation has occurred;
- micronizing a quantity of cyclodextrin and performing a quality control of the micronized cyclodextrin;
- micronizing a first material selected from the group consisting of ergocalciferol and cholecalciferol and performing a quality control of the micronized first material;
- micronizing a second material selected from the group consisting of Withania somnifera and ginseng;
- micronizing a third material selected from the group consisting of free fatty acids, essential amino acids, and HMB-free acid;
- dissolving a phospholipid in a solvent and adding the second material to form a phytosome complex and drying the phytosome complex;
- blending the micronized DHEA derivative with the cyclodextrin until both have the same particle size;
- adding the phytosome complex to the micronized DHEA derivative, with the cyclodextrin and the first material;
- assigning each of the DHEA derivative, the cyclodextrin, the first material, the second material, and the third material to a polarity-specific profile based on solubility and absorption characteristics;
- and
- incorporating lipophilic compounds into lipidic carriers and incorporating hydrophilic compounds into hydrophilic carriers.
A targeted release dietary supplement delivery system comprising:
- a quantity of a micronized DHEA derivative comprising 4-androstene-3b-ol-one propionate in the form of a dry, free-flowing powder of less than ten microns and having no chemical degradation;
- a quantity of micronized cyclodextrin;
- a first micronized material selected from the group consisting of ergocalciferol and cholecalciferol;
- a second micronized material selected from the group consisting of Withania somnifera and ginseng;
- a third micronized material selected from the group consisting of free fatty acids, essential amino acids, and HMB-free acid;
- a phospholipid dissolved in a solvent and added to the second micronized material and dried to form a phytosome complex;
- wherein the micronized DHEA derivative is blended with the cyclodextrin until both have the same particle size;
- wherein the phytosome complex is added to the micronized DHEA derivative, along with the cyclodextrin and the first micronized material;
- wherein each of the DHEA derivative, the cyclodextrin, the first micronized material, the second micronized material, and the third micronized material are assigned to a polarity-specific profile based on solubility and absorption characteristics;
- and
- wherein lipophilic compounds are incorporated into lipidic carriers and hydrophilic compounds are incorporated into hydrophilic carriers.
Dependencies are inferred from the claim text.